272 related articles for article (PubMed ID: 29954863)
21. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment.
Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ
Curr Heart Fail Rep; 2024 May; ():. PubMed ID: 38775878
[TBL] [Abstract][Full Text] [Related]
22. Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers of
Kaniper S; Lynch D; Owens SM; Ibric L; Vabishchevich Y; Nyantakyi N; Chun F; Sam L; Fabrizio C; Hamad E; Gerhard GS
J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38541013
[TBL] [Abstract][Full Text] [Related]
23. Eplontersen: First Approval.
Nie T
Drugs; 2024 Apr; 84(4):473-478. PubMed ID: 38413492
[TBL] [Abstract][Full Text] [Related]
24. Amyloid fibril polymorphism in the heart of an ATTR amyloidosis patient with polyneuropathy attributed to the V122Δ variant.
Ahmed Y; Nguyen BA; Afrin S; Singh V; Evers B; Singh P; Pedretti R; Wang L; Bassett P; Del Carmen Fernandez-Ramirez M; Pekala M; Kluve-Beckerman B; Saelices L
bioRxiv; 2024 May; ():. PubMed ID: 38766262
[TBL] [Abstract][Full Text] [Related]
25. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.
Quarta CC; Fontana M; Damy T; Catini J; Simoneau D; Mercuri M; Garcia-Pavia P; Maurer MS; Palladini G
Front Cardiovasc Med; 2022; 9():1073503. PubMed ID: 36606280
[TBL] [Abstract][Full Text] [Related]
26. Multi-organ structural homogeneity of amyloid fibrils in ATTRv-T60A amyloidosis patients, revealed by Cryo-EM.
Fernandez-Ramirez MDC; Nguyen BA; Singh V; Afrin S; Evers B; Basset P; Wang L; Pękała M; Ahmed Y; Singh P; Canepa J; Wosztyl A; Li Y; Saelices L
bioRxiv; 2024 May; ():. PubMed ID: 38798519
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines.
Benson MD; Dasgupta NR; Rao R
Ther Clin Risk Manag; 2020; 16():749-758. PubMed ID: 32884276
[TBL] [Abstract][Full Text] [Related]
28. Detection of Circulating Transthyretin Amyloid Aggregates in Plasma: A Novel Biomarker for Transthyretin Amyloidosis.
Pedretti R; Wang L; Hanna M; Benson MD; Grodin JL; Tang WHW; Masri A; Saelices L
Circulation; 2024 May; 149(21):1696-1699. PubMed ID: 38768274
[No Abstract] [Full Text] [Related]
29. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis.
Köppen J; Kleinschmidt M; Morawski M; Rahfeld JU; Wermann M; Cynis H; Hegenbart U; Daniel C; Roßner S; Schilling S; Schulze A
Amyloid; 2024 May; ():1-11. PubMed ID: 38801321
[TBL] [Abstract][Full Text] [Related]
30. Physiological IgM class catalytic antibodies selective for transthyretin amyloid.
Planque SA; Nishiyama Y; Hara M; Sonoda S; Murphy SK; Watanabe K; Mitsuda Y; Brown EL; Massey RJ; Primmer SR; O'Nuallain B; Paul S
J Biol Chem; 2014 May; 289(19):13243-58. PubMed ID: 24648510
[TBL] [Abstract][Full Text] [Related]
31. Wild-type Transthyretin Amyloid Deposition in an Ascending Aortic Aneurysm.
Hoteit A; Casimero FVC; Stone JR; Cameron D; Isselbacher EM; Seyedsadjadi R; Gaggin HK
JACC Case Rep; 2024 May; 29(9):102311. PubMed ID: 38576771
[TBL] [Abstract][Full Text] [Related]
32. Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy.
Dorbala S; Clerc OF
JACC CardioOncol; 2021 Oct; 3(4):547-549. PubMed ID: 34729527
[TBL] [Abstract][Full Text] [Related]
33. Correction to "Wild-type Shadoo proteins convert to amyloid-like forms under native conditions".
J Neurochem; 2024 May; ():. PubMed ID: 38809770
[No Abstract] [Full Text] [Related]
34. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
[TBL] [Abstract][Full Text] [Related]
35. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.
Monteiro C; Martins da Silva A; Ferreira N; Mesgarzadeh J; Novais M; Coelho T; Kelly JW
Amyloid; 2018 Jun; 25(2):120-128. PubMed ID: 29993288
[TBL] [Abstract][Full Text] [Related]
37. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.
Leach BI; Zhang X; Kelly JW; Dyson HJ; Wright PE
Biochemistry; 2018 Jul; 57(30):4421-4430. PubMed ID: 29972637
[TBL] [Abstract][Full Text] [Related]
38. Retinol-Binding Protein Interferes with Transthyretin-Mediated β-Amyloid Aggregation Inhibition.
Mangrolia P; Murphy RM
Biochemistry; 2018 Aug; 57(33):5029-5040. PubMed ID: 30024734
[TBL] [Abstract][Full Text] [Related]
39. The two shapes of the Tau protein.
Kelly JW
Elife; 2018 Jul; 7():. PubMed ID: 29988017
[TBL] [Abstract][Full Text] [Related]
40. Cryo-EM structure of alpha-synuclein fibrils.
Guerrero-Ferreira R; Taylor NM; Mona D; Ringler P; Lauer ME; Riek R; Britschgi M; Stahlberg H
Elife; 2018 Jul; 7():. PubMed ID: 29969391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
